CoChat

Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus

Akuta, Norio, Kawamura, Yusuke, Watanabe, Chizuru, Nishimura, Akihiro, Okubo, Minoru, Mori, Yasumichi, Fujiyama, Shunichiro, Sezaki, Hitomi, Hosaka, Tetsuya, Kobayashi, Masahiro, Kobayashi, Mariko, Saitoh, Satoshi, Suzuki, Fumitaka, Suzuki, Yoshiyuki, Arase, Yasuji, Ikeda, Kenji, Kumada, Hiromitsu · 2019 · Hepatology Research
Cited by 107

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Aim: The aim of this study was to investigate the therapeutic potential of sodium glucose cotransporter 2 inhibitor (SGLT2I) as an effective therapeutic option for non‐alcoholic fatty liver disease (NAFLD). Methods: In this prospective study, nine patients with NAFLD complicated by type 2 diabetes mellitus (DM), were introduced to the regimen of canagliflozin 100 mg once daily for 24 weeks and were evaluated by liver histology at pretreatment and at 24 weeks after the start of treatment. The primary outcome was histological improvement, defined as a decrease in NAFLD activity score of one point or more without worsening in fibrosis stage. Glucose metabolism was evaluated based on the meal tolerance test. The usefulness of extracellular and exosome microRNA‐122 (miR‐122) as early predictors of histological improvement was investigated. Results: All of the nine patients achieved histological improvement. Scores of steatosis, lobular inflammation, ballooning, and fibrosis stage decreased by 78%, 33%, 22%, and 33% at 24 weeks compared to the pretreatment, respectively. Six patients showed improvement in insulin resistance, and the other three patients showed partial improvement of insulin secretion function. Six patients, who showed a decrease in both extracellular and exosome miR‐122 ratios (the ratio of miR‐122 levels at 1 day after treatment to that at baseline), showed histological improvement. Furthermore, one patient, who showed a decrease in exosome miR‐122 ratios regardless of the increase in extracellular miR‐122 ratios, also showed decreases in NAFLD activity score and fibrosis stage. Conclusion: A prospective study showed that SGLT2I for NAFLD complicated by DM improved histological features in connection with glucose metabolism. This trial was registered as clinical trial UMIN000018166.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/hepr.13304

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 107

Metadata

Authors
Akuta, N., Kawamura, Y., Watanabe, C., Nishimura, A., Okubo, M., Mori, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., Saitoh, S., Suzuki, F., Suzuki, Y., Arase, Y., Ikeda, K., & Kumada, H.
Venue
Hepatology Research
Publisher
Wiley
Published
2019-02-06
Volume
49
Issue
5
Pages
531-539
ISSN
  • 1386-6346 (ISSN-L)
  • 1872-034X
OpenAlex
W2906364339
Cited by
107
References
8
FWCI
9.55
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus. https://app.cochat.ai/papers/10.1111/hepr.13304
The paper
Akuta, N., Kawamura, Y., Watanabe, C., Nishimura, A., Okubo, M., Mori, Y., Fujiyama, S., Sezaki, H., Hosaka, T., Kobayashi, M., Kobayashi, M., Saitoh, S., Suzuki, F., Suzuki, Y., Arase, Y., Ikeda, K., & Kumada, H. (2019). Impact of sodium glucose cotransporter 2 inhibitor on histological features and glucose metabolism of non‐alcoholic fatty liver disease complicated by diabetes mellitus. Hepatology Research. https://doi.org/10.1111/hepr.13304

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.